How well does Koselugo(Selumetinib) work?

KOSELUGO demonstrates significant efficacy in reducing tumor burden in pediatric NF1 patients with inoperable plexiform neurofibromas.

Clinical Efficacy of KOSELUGO in NF1-Associated Plexiform Neurofibromas

KOSELUGO has shown a clinically meaningful therapeutic effect in pediatric patients with NF1 and symptomatic, inoperable plexiform neurofibromas.

In pivotal clinical trials, the overall response rate was 66%, defined as at least a 20% reduction in tumor volume confirmed by imaging. The median time to response was 7.2 months, with a substantial proportion of patients maintaining response for 24 months or longer. KOSELUGO offers a targeted treatment option for a population with limited alternatives, improving morbidity associated with tumor burden. Efficacy in other populations or tumor types is not specified in the description.

Related Columns

Selumetinib(Koselugo)

KOSELUGO (selumetinib) is indicated for the treatment of pediatric patients...

WeChat Scan
Free Inquiry

Selumetinib effect

Selumetinib is a targeted therapy drug that is primarily used to treat specific types of neurofibromatosis. This article will delve into the mechanism of action of Selumetinib, its clinical efficacy, ...

Efficacy of Selumetinib

Selumetinib is a targeted drug specifically designed for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This article will detail the efficacy of Selumetinib, ...